News archive

Gene 'fusions' trigger prostate cancer

THURSDAY 2 AUGUST 2007

US researchers have shed new light on the way prostate cancers develop, in research that could one day lead to new tests and treatments for the disease.

The scientists, from the University of Michigan Comprehensive Cancer Centre, found that two particular chromosomes - the long stretches of DNA inside every cell - are able to trade chunks of DNA with each other, scrambling certain genes along their length.

This gene-scrambling generates new 'fusion' genes, made of one half from one gene, and one half from another.

These fusion genes then override the cell's normal mechanisms and encourage it to grow out of control.

The researchers were able to identify a series of genes frequently involved in such fusions, and speculated that each may lead to a different 'type' of prostate cancer.

Dr Arul Chinnaiyan, director of the Michigan Centre for Translational Pathology, commented: "Each of these switches, or gene fusions, represent different molecular subtypes.

"It's a more complex disease and potentially needs to be treated differently in each patient," he added.

The researchers suggested that choice of treatment could therefore depend on which gene fusion is involved.

For example, the effects of four of the scrambled genes were found to be controlled by male sex hormones (androgens), which are known to fuel prostate cancer.

Dr Chinnaiyan explained that identifying which gene fusion was responsible for a person's disease could affect the choice of treatment. "We would not want to give androgen to someone whose prostate cancer gene fusion is not regulated by androgen," he said.

"Long-term, we hope this will lead to better therapies to treat prostate cancer. The key challenge is to find a drug that would go after this gene fusion," he added.

Josephine Querido, senior science information officer at Cancer Research UK, said that although the research is still at an early stage, the results "hold great potential".

"Knowing more about the key genetic changes in a person's tumour will help doctors to tailor treatment to individual patients," she said.

"We hope that this research will lead to better diagnosis and improved treatments for prostate cancer patients in the future."

News provided by Adfero in collaboration with Cancer Research UK. Please note that all copy is © Adfero Ltd and does not reflect the views or opinions of Cancer Research UK unless explicitly stated.


* Skin cancer fears may increase risk of bone thinning disease
* New drug shows promise against aggressive prostate cancer in small trial
* Cervical cancer vaccination programme to be extended
* Food firms still marketing unhealthy products to children
* Study finds little benefit from breast self-exams, but being 'breast-aware' is vital
* 'Massive' increase in cancer survival
* Magnolia compound may have anti-cancer properties
* Herceptin 'may target breast cancer stem cells'
* Public unaware of link between smoking and bladder cancer
* Younger women's breast cancer is genetically different
A - Z index A - Z index
Contact us Contact us
Donate now Donate now
Glossary Glossary
Print this page Print this page


AddThis Feed Button

Find out more
 
 
About this site   Accessibility   Donate now   Privacy   Site Map   Terms & Conditions   Top of page

Cancer Research UK is a registered charity No. 1089464.
Registered as a company limited by guarantee in England & Wales No. 4325234.
Registered address 61 Lincoln's Inn Fields, London, WC2A 3PX.